Gland Pharma Secures Overwhelming Approval to Appoint Mr. Xingli Wang as Non-Executive Director
Postal ballot remote e-voting results show 97.07% votes in favor, confirming appointment in November 2026
Gland Pharma Limited announced the appointment of Mr. Xingli Wang as Non-Executive and Non-Independent Director after securing over 97% member approval through remote e-voting in a postal ballot conducted in November 2026. The resolution passed with extensive shareholder participation, including promoter and institutional investors.
Gland Pharma Limited
Change in Management
Gland Pharma Limited announced that its members have approved the appointment of Mr. Xingli Wang as a Non-Executive and Non-Independent Director, with the resolution passing by a large majority in a postal ballot held on November 5, 2026.
The postal ballot voting was conducted remotely via electronic voting, covering promoter groups, public institutions, and non-institutional shareholders.
Voting results showed nearly 85.56% of total outstanding shares participated, with approximately 97.07% of votes in favor of the appointment resolution.
Promoter and promoter group shareholders accounted for almost 99.9999% in favor, while public institutional shareholders voted with 93.69% in favor, and public non-institutional shareholders voted 99.75% in favor.
The resolution was passed as an ordinary resolution under the SEBI Listing Regulations and the Companies Act, 2013.
The appointment was scrutinized by D Soumya, Company Secretary and Associate Partner of RVR & Associates, who confirmed the proper conduct and fairness of the voting process.
Highlights
- Resolution to appoint Mr. Xingli Wang as Non-Executive and Non-Independent Director passed on November 5, 2026.
- Approximate 85.56% of total outstanding shares participated in voting through remote e-voting.
- Overall 97.07% votes cast were in favor of the resolution.
- Promoter and promoter group voted 99.9999% in favor, with no votes against.
- Public institutions voted 93.69% in favor and 6.31% against; public non-institutions voted 99.75% in favor.
- Scrutinizer report from RVR & Associates confirmed transparent and compliant process.
Key Data Snapshot
What happened
- Gland Pharma Limited's shareholders approved the appointment of Mr. Xingli Wang as a Non-Executive and Non-Independent Director through a postal ballot conducted by remote e-voting ending November 5, 2026.
- The voting resolution passed with over 97% votes in favor from all shareholders participating.
Key details
- Total voting turnout represented about 85.56% of the company's outstanding shares.
- Promoter and promoter group shareholders voted nearly unanimously in favor, with 99.9999% support.
- Public institutional shareholders voted 91.20% on shares held with 93.69% approval for the resolution.
- Public non-institution shareholders voted with 0.79% participation and 99.75% approval.
- The appointment is classified as an ordinary resolution under SEBI regulations and company bylaws.
Regulatory and governance context
- The vote was conducted under the framework of the Companies Act, 2013, SEBI Listing Regulations 2015, and applicable MCA Circulars dating up to 2025.
- The scrutiny and certification of the voting process were performed by D Soumya, Company Secretary in whole-time practice and Associate Partner at RVR & Associates.
- The appointment complies with mandates for board composition reflecting non-executive and non-independent directorships.
Highlights
- Resolution to appoint Mr. Xingli Wang as Non-Executive and Non-Independent Director passed on November 5, 2026.
- Approximate 85.56% of total outstanding shares participated in voting through remote e-voting.
- Overall 97.07% votes cast were in favor of the resolution.
- Promoter and promoter group voted 99.9999% in favor, with no votes against.
- Public institutions voted 93.69% in favor and 6.31% against; public non-institutions voted 99.75% in favor.
- Scrutinizer report from RVR & Associates confirmed transparent and compliant process.
Disclosures
- Companies Act, 2013
- SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- MCA Circulars Nos 14/2020 to 03/2025
Promoter and promoter group are not interested in the agenda/resolution.
Source Information
More News on Change in Management
View allLatest corporate announcements and market updates in Change in Management.
Oriental Aromatics Appoints Ms. Amruda Vivek Nair as Independent Director for a Five-Year Term
Oriental Aromatics Limited has proposed the appointment of Ms. Amruda Vivek Nair as an Independent Director for a period of five years starting November 4, 2026, with member approval sought through a postal ballot conducted via remote electronic voting.
Read Full StoryJ.K. Shah Commerce Education Limited Names Authorized Key Managerial Personnel for Event Disclosures
J.K. Shah Commerce Education Limited has designated three key managerial personnel authorized to assess materiality and handle disclosures to stock exchanges in compliance with SEBI Listing Regulations.
Read Full StoryAbans Financial Services Initiates Postal Ballot for Director Appointment and Key Related Party Transactions
Abans Financial Services Limited has launched a postal ballot via remote e-voting to obtain shareholder approval for appointing Mr. Mayank Mahesh Mundhra as Director and Whole-Time Executive Director, and to approve material related party transactions conducted by its subsidiary Abans Middle East FZCO with promoter-related entities.
Read Full Story